Loading...

Alexa Fluor® 647 anti-human/mouse Granzyme B Antibody

Pricing & Availability
Clone
GB11 (See other available formats)
Regulatory Status
RUO
Other Names
Granzyme-2, serine protease B, CCP1, Asp-ase, CTLA-1
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
1_GB11_A647_110409
Human peripheral blood lymphocytes were surface stained with CD8 PE, then intracellularly stained with Granzyme B (clone GB11) Alexa Fluor® 647 (top) or mouse IgG1 Alexa Fluor® 647 isotype control (middle).
  • 1_GB11_A647_110409
    Human peripheral blood lymphocytes were surface stained with CD8 PE, then intracellularly stained with Granzyme B (clone GB11) Alexa Fluor® 647 (top) or mouse IgG1 Alexa Fluor® 647 isotype control (middle).
  • 2_GB11_A647_082409
  • GB11_AF647_1_082911
    C57BL/6 mouse splenocytes were stimulated with plate-bound anti-mouse TCR-β for 2 days, then surface stained with CD8 PE and intracellularly stained with Granzyme B (clone GB11) Alexa Fluor® 647.
Compare all formats See Alexa Fluor® 647 spectral data
Cat # Size Price Quantity Check Availability Save
515405 25 tests 137€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
515406 100 tests 292€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Granzyme B is a 32 kD serine protease, also known as granzyme-2, serine protease B, CCP1, Asp-ase, and CTLA-1. Granzyme B is abundantly stored in the granules of cytotoxic T lymphocytes and NK cells. Low level of expression has been reported in granulocytes, B cells, and activated dendritic cells. Granzyme B is crucial for rapid induction of cell death and apoptosis through interaction with mannose-6-phosphate receptor.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Mouse
Reported Reactivity
Rat
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography and conjugated with Alexa Fluor® 647 under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

* Alexa Fluor® 647 has a maximum emission of 668 nm when it is excited at 633nm / 635nm.


Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.

View full statement regarding label licenses
Excitation Laser
Red Laser (633 nm)
Application References

(PubMed link indicates BioLegend citation)
  1. Wever PC, et al. 1998. Immunology. 93:383
  2. Arens R, et al. 2004. J. Exp. Med. 199:1595
  3. Lima M, et al. 2003. Am. J. Pathol. 163:763
  4. Wiede F, et al. 2014. J Autoimmun. 53:105. PubMed
  5. Baker GF, et al. 2014. Cancer Res. 74:5079. PubMed
  6. Nacer A, et al. 2014. PLoS Pathog. 10:1004528. PubMed
  7. Sharma SK, et al. 2015. J Immunol. 194:5529. PubMed
Product Citations
  1. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  2. Guo A, et al. 2022. Nature. 607:135. PubMed
  3. Jeon Y, et al. 2022. Cancers (Basel). 14:. PubMed
  4. Wu Z, et al. 2023. EMBO Rep. 24:e56524. PubMed
  5. Oh G, et al. 2023. J Clin Invest. 133:. PubMed
  6. Corria-Osorio J, et al. 2023. Nat Immunol. 24:869. PubMed
  7. Khan A, et al. 2015. J Virol. 89:3776. PubMed
  8. Saxena V, et al. 2022. Cell Rep. 39:110727. PubMed
  9. Wang X, et al. 2022. Sci Adv. 8:eabn0071. PubMed
  10. Lin YH 2023. Immunity. 56(1):207-223.e8. PubMed
  11. Jaiswal A, et al. 2022. Cancer Cell. 40:524. PubMed
  12. Shimizu K, et al. 2020. Molecular Cell. 77(5):937-950.e6.. PubMed
  13. Page N, et al. 2018. Immunity. 48:937. PubMed
  14. Donnarumma T, et al. 2016. Cell Rep. 17:1571-1583. PubMed
  15. Kim D, et al. 2021. Nanomicro Lett. 13:31. PubMed
  16. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
  17. Mogilenko DA, et al. 2020. Immunity. 54(1):99-115.e12. PubMed
  18. Coleby R, et al. 2021. Clin Exp Rheumatol. :39. PubMed
  19. Álvaro de Mingo Pulido et al. 2018. Cancer cell. 33(1):60-74 . PubMed
  20. Pachnio A, et al. 2016. PLoS Pathog. 12: 1005832. PubMed
  21. Chen M, et al. 2021. Cancers (Basel). 13:. PubMed
  22. Liu W, et al. 2021. Cell Mol Immunol. 18:2660. PubMed
  23. Davari K, et al. 2021. J Immunother Cancer. 9:. PubMed
  24. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  25. Wu J, et al. 2020. Sci Adv. 6:eaba3458. PubMed
  26. Wiede F, et al. 2021. Cancer Discov. Online ahead of print. PubMed
  27. Fumagalli V, et al. 2020. J Exp Med. :217. PubMed
  28. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  29. Lin JR et al. 2018. eLife. 7 pii: e31657. PubMed
  30. Trotta E, et al. 2018. Nat Med. 24:1005. PubMed
  31. Terashima Y, et al. 2020. Nat Commun. 11:609. PubMed
  32. Ng W, et al. 2021. Pharm Biol. 59:47:00. PubMed
  33. Alkasalias T, et al. 2022. Cell Death Discov. 8:464. PubMed
  34. Ping Y, et al. 2020. Front Cell Dev Biol. 0.890972222. PubMed
  35. Jackstadt R, et al. 2019. Cancer Cell. 36:319. PubMed
  36. Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed
  37. Walk J, et al. 2019. Nat Commun. 10:874. PubMed
  38. Carozza JA, et al. 2020. Nat Cancer. 184:1. PubMed
  39. Jankeel A, et al. 2020. J Virol. :94. PubMed
  40. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  41. Schofield DJ, et al. 2021. MAbs. 13:1857100. PubMed
  42. Carpentier A, et al. 2017. PLoS One. 10.1371/journal.pone.0181403. PubMed
  43. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  44. Li J, et al. 2018. Immunity. 49:178. PubMed
  45. Fan Z, et al. 2020. EMBO Mol Med. 12:e11571. PubMed
  46. Pais Ferreira D, et al. 2020. Immunity. 53(5):985-1000.e11. PubMed
  47. Souza COS, et al. 2021. iScience. 24(6):102548. PubMed
  48. Zhang T, et al. 2022. Oncogene. . PubMed
  49. Pardy RD, et al. 2021. Nat Commun. 12:4051. PubMed
  50. Grifoni A, et al. 2020. Cell. 181(7):1489-1501.e15.. PubMed
  51. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  52. Gordon-Alonso M,et al. 2017. Nat. Commun. 10.1038/s41467-017-00925-6. PubMed
  53. Wang B, et al. 2021. J Immunother Cancer. 9:. PubMed
  54. Griffin B, et al. 2017. Nat Commun. 10.1038/ncomms15743. PubMed
  55. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  56. Zhang Y, et al. 2018. Nat Commun. 9:6. PubMed
  57. Ambrose AR, et al. 2020. Proc Natl Acad Sci U S A. 117:23717. PubMed
  58. Chen H, et al. 2021. iScience. 24:103387. PubMed
  59. Bartolacci C, et al. 2018. Cancer Immunol Res. 1.281944444. PubMed
  60. Ren C, et al. 2022. J Cell Mol Med. 26:1071. PubMed
  61. Lou Y, et al. 2021. Int J Mol Sci. 22:. PubMed
  62. Hamaidi I, et al. 2020. Cell Metabolism. 32(3):420-436.e12. PubMed
  63. Rydyznski Moderbacher C, et al. 2020. Cell. 183(4):996-1012.e19. PubMed
  64. Kim J, et al. 2016. Sci Rep. 6:27615. PubMed
  65. Khuzwayo S, et al. 2021. Front Immunol. 12:631410. PubMed
  66. Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
  67. Iwata TN, et al. 2018. Mol Cancer Ther. 17:1494. PubMed
  68. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  69. Yao C, et al. 2018. Autophagy. 1.854861111. PubMed
  70. Li W, et al. 2020. Immunity. 53(2):456-470. PubMed
  71. Huang H, et al. 2021. Cell. 184(5):1245-1261.e21. PubMed
  72. Chitirala P, et al. 2020. eLife. 9:00. PubMed
  73. Srivastava R, et al. 2015. J Immunol. 194:2232. PubMed
  74. Pachnio A, et al. 2015. J Immunol. 195: 3803 - 3815. PubMed
  75. Mathewson ND, et al. 2021. Cell. 184(5):1281-1298.e26. PubMed
  76. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
  77. Dhayade S, et al. 2020. Nutrients. 12:. PubMed
  78. Pantelidou C, et al. 2022. NPJ Breast Cancer. 8:102. PubMed
  79. Wu R, et al. 2020. J Immunother Cancer. 8:00. PubMed
  80. Mackroth M, et al. 2016. PLoS Pathog. 12:e1005909. PubMed
  81. Xian S, et al. 2021. EMBO Rep. 22:e52509. PubMed
  82. Woods E, et al. 2021. NPJ Vaccines. 6:117. PubMed
  83. Lee HN, et al. 2022. JCI Insight. 7:. PubMed
  84. Boulch M, et al. 2021. Sci Immunol. 6:. PubMed
  85. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  86. Pflügler S, et al. 2020. Commun Biol. 3:252. PubMed
  87. Coomes S, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.47. PubMed
  88. Peng W, et al. 2020. Antimicrob Agents Chemother. 64:. PubMed
  89. Dai B, et al. 2021. Cell Reports Medicine. 2(8):100381. PubMed
  90. Mishra GP, et al. 2022. Cell Mol Life Sci. 79:429. PubMed
  91. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
RRID
AB_2294995 (BioLegend Cat. No. 515405)
AB_2294995 (BioLegend Cat. No. 515406)

Antigen Details

Structure
32 kD serine protease
Distribution

Cytotoxic T-cells and NK cells, low on granulocytes, B cells and activated dendritic cells

Function
Induction of cell death and apoptosis
Ligand/Receptor
Mannose-6-phosphate receptor
Cell Type
B cells, Dendritic cells, NK cells, T cells
Biology Area
Cell Biology, Immunology, Innate Immunity, Neuroscience
Molecular Family
Enzymes and Regulators, Proteases
Antigen References

1. Estebanez-Perpina E, et al. 2000. Biol Chem. 381:1203
2. Griffiths GM. And S. Isaaz, et al. 1993. J. Cell Biol. 120:885
3. Spaeny-Dekking EH, et al. 1998. J. Immunol. 160:3610
4. Wagner C, et al. 2008. Mol. Immunol. 45:1761

Gene ID
3002 View all products for this Gene ID 14939 View all products for this Gene ID 171528 View all products for this Gene ID
UniProt
View information about Granzyme B on UniProt.org
Go To Top Version: 3    Revision Date: 06.27.2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account